https://rgs-receptor.com
Anti-programmed death ligand 1 (PD-L1) antibody treatment in three patients resulted in hypopituitarism, which presented six to nine months after treatment, demonstrating a similar time course to that seen with anti-PD-1 antibody. Rare though immune-related hypopituitarism may be after receiving atezolizumab-bevacizumab treatment, vigilance is crucial to detect any potential hypopituitarism that might arise during the administration of this treatment. A malformation of the aortic structure leads to the right aortic arch; this stands in contrast to Kommerell's d
Mi piace
Commento
Condividi
